Thompson Davis & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Thompson Davis & Co’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-27	Closed	-$12K	–	992
2017 Q3	$12K	Buy	+27	New	+$12.8K	0.02%	639
2017 Q2	–	Sell	-45	Closed	-$17K	–	1156
2017 Q1	$17K	Hold	45	–	–	0.02%	551
2016 Q4	$17K	Hold	45	–	–	0.03%	549
2016 Q3	$18K	Buy	+45	New	+$18.1K	0.03%	516
2015 Q4	–	Sell	-20	Closed	-$9K	–	1181
2015 Q3	$9K	Sell	20 -40	-67%	-$21.5K	0.01%	688
2015 Q2	$31K	Buy	60 +40	+200%	+$19.5K	0.04%	419
2015 Q1	$9K	Sell	20 -57	-74%	-$24.2K	0.01%	764
2014 Q4	$32K	Sell	77 -303	-80%	-$119K	0.04%	383
2014 Q3	$137K	Buy	380 +360	+1,800%	+$121K	0.18%	122
2014 Q2	$6K	Hold	20	–	–	0.01%	579
2014 Q1	$6K	Hold	20	–	–	0.01%	603
2013 Q4	$6K	Buy	+20	New	+$5.75K	0.01%	541

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Thompson Davis & Co's REGN Position: Q4 2017 in Review

Thompson Davis & Co sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 27 shares — an estimated $12K sold.

Thompson Davis & Co first reported a position in REGN in Q4 2013 and held it in 12 quarters. The position peaked at $137K in Q3 2014. 639 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

Thompson Davis & Co reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Thompson Davis & Co sold 27 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $12K.
Thompson Davis & Co first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 12 quarters.
Thompson Davis & Co's Regeneron Pharmaceuticals position peaked at $137K in Q3 2014.
639 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.